VRDN vs. HIMS, RDNT, GH, OPCH, SHC, VCYT, BTSG, LFST, SGRY, and CON
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Hims & Hers Health (HIMS), RadNet (RDNT), Guardant Health (GH), Option Care Health (OPCH), Sotera Health (SHC), Veracyte (VCYT), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Surgery Partners (SGRY), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs.
Hims & Hers Health (NYSE:HIMS) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability.
In the previous week, Hims & Hers Health had 12 more articles in the media than Viridian Therapeutics. MarketBeat recorded 17 mentions for Hims & Hers Health and 5 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.13 beat Hims & Hers Health's score of 0.31 indicating that Viridian Therapeutics is being referred to more favorably in the news media.
Hims & Hers Health has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.
Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
63.5% of Hims & Hers Health shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 0.7% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Hims & Hers Health has a net margin of 8.19% compared to Viridian Therapeutics' net margin of -85,127.16%. Hims & Hers Health's return on equity of 10.97% beat Viridian Therapeutics' return on equity.
Hims & Hers Health currently has a consensus target price of $25.13, indicating a potential downside of 7.81%. Viridian Therapeutics has a consensus target price of $35.70, indicating a potential upside of 98.28%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.
Viridian Therapeutics received 33 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 78.72% of users gave Viridian Therapeutics an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote.
Summary
Hims & Hers Health beats Viridian Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 1/17/2025 by MarketBeat.com Staff
Free VRDN Stock Alerts